Last Updated : February 12, 2020
Details
Generic Name:
Entrectinib
Project Status:
Withdrawn
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
TBD
Project Line:
Reimbursement Review
Project Number:
PC0157-000
Tumour Type:
Other
Indications:
Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion-Positive Solid Tumours
Funding Request:
For the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients.
Review Status:
Withdrawn
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
Clarification:
Hoffmann-La Roche Limited has requested a voluntary withdrawal of the pCODR 10157 Entrectinib (TBD) for NTRK+ solid tumours submission.
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : February 12, 2020